MXPA01010899A - Metodo para mejorar la eficacia de agentes anti-tumor. - Google Patents

Metodo para mejorar la eficacia de agentes anti-tumor.

Info

Publication number
MXPA01010899A
MXPA01010899A MXPA01010899A MXPA01010899A MXPA01010899A MX PA01010899 A MXPA01010899 A MX PA01010899A MX PA01010899 A MXPA01010899 A MX PA01010899A MX PA01010899 A MXPA01010899 A MX PA01010899A MX PA01010899 A MXPA01010899 A MX PA01010899A
Authority
MX
Mexico
Prior art keywords
tumor
epo
cisplatin
hematocrit
erythropoietin
Prior art date
Application number
MXPA01010899A
Other languages
English (en)
Spanish (es)
Inventor
Steven M Piver
Original Assignee
Health Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Health Research Inc filed Critical Health Research Inc
Publication of MXPA01010899A publication Critical patent/MXPA01010899A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • External Artificial Organs (AREA)
MXPA01010899A 1999-04-27 2000-04-24 Metodo para mejorar la eficacia de agentes anti-tumor. MXPA01010899A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/300,124 US6171620B1 (en) 1999-04-27 1999-04-27 Method of enhancing the efficacy of anti-tumor agents
PCT/US2000/011000 WO2000064455A1 (en) 1999-04-27 2000-04-24 Method of enhancing the efficacy of anti-tumor agents

Publications (1)

Publication Number Publication Date
MXPA01010899A true MXPA01010899A (es) 2003-06-24

Family

ID=23157813

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA01010899A MXPA01010899A (es) 1999-04-27 2000-04-24 Metodo para mejorar la eficacia de agentes anti-tumor.

Country Status (18)

Country Link
US (3) US6171620B1 (cg-RX-API-DMAC7.html)
EP (1) EP1212068A4 (cg-RX-API-DMAC7.html)
JP (1) JP2002542296A (cg-RX-API-DMAC7.html)
KR (1) KR100693796B1 (cg-RX-API-DMAC7.html)
CN (1) CN1188137C (cg-RX-API-DMAC7.html)
AU (1) AU781301B2 (cg-RX-API-DMAC7.html)
BG (1) BG64940B1 (cg-RX-API-DMAC7.html)
BR (1) BR0010082A (cg-RX-API-DMAC7.html)
CA (1) CA2368618C (cg-RX-API-DMAC7.html)
HU (1) HUP0200840A3 (cg-RX-API-DMAC7.html)
IL (1) IL146012A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA01010899A (cg-RX-API-DMAC7.html)
NO (1) NO20015227L (cg-RX-API-DMAC7.html)
NZ (1) NZ514521A (cg-RX-API-DMAC7.html)
PL (1) PL350918A1 (cg-RX-API-DMAC7.html)
RU (1) RU2271829C2 (cg-RX-API-DMAC7.html)
WO (1) WO2000064455A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200108012B (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7678391B2 (en) * 2000-04-26 2010-03-16 Queen's University At Kingston Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
US20050142217A1 (en) * 2000-04-26 2005-06-30 Adams Michael A. Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
JP2003531179A (ja) 2000-04-26 2003-10-21 クイーンズ ユニバーシティ アット キングストン 悪性細胞表現型に対し一酸化窒素模倣体を使用する処方および方法
WO2004022593A2 (en) * 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
PL2368554T3 (pl) 2003-04-08 2015-05-29 Progenics Pharm Inc Preparaty farmaceutyczne zawierające metylonaltrekson
DE10361813A1 (de) * 2003-12-30 2005-09-08 Bionethos Holding Gmbh Verfahren zur Regeneration von Gewebe
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
MX2007010833A (es) * 2005-03-07 2009-02-17 Univ Chicago Uso de antagonistas opioides para atenuar proliferacion y migracion de células endoteliales.
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
WO2008065372A2 (en) 2006-11-28 2008-06-05 Nautilus Biotech, S.A. Modified erythropoietin polypeptides and uses thereof for treatment
MX2009010550A (es) 2007-03-29 2009-12-14 Progenics Pharm Inc Formas de cristal de bromuro de (r)-n-metilnaltrexona y uso de las mismas.
JP5469593B2 (ja) 2007-03-29 2014-04-16 ワイス・エルエルシー 末梢性オピオイド受容体アンタゴニストおよびその使用
WO2008121348A2 (en) 2007-03-29 2008-10-09 Progenics Pharmaceuticals, Inc. Peripheral opioid receptor antagonists and uses thereof
AU2008349873B2 (en) 2008-02-06 2014-02-13 Progenics Pharmaceuticals, Inc. Preparation and use of (R),(R)-2,2'-bis-methylnaltrexone
CA2719134C (en) 2008-03-21 2015-06-30 The University Of Chicago Treatment with opioid antagonists and mtor inhibitors
EP2310038A4 (en) * 2008-05-15 2012-03-14 Edison Pharmaceuticals Inc TREATMENT OF HEARING AND BALANCE OF IMPROVENCE WITH COMPOUNDS WITH ERYTHROPOETIN EFFECT
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
PL230756B1 (pl) * 2015-09-11 2018-12-31 Univ Medyczny W Bialymstoku Erytropoetyna oraz inhibitor kinazy Brutona w postaci 2- cyjan o-N-( 2,5-dibromofenylo)- 3-hydroksy-2- butenamidu do zastosowania jako lek oraz ich zastosowanie do wytwarzania leku do terapii nowotworu
JPWO2019083023A1 (ja) * 2017-10-26 2020-11-12 国立大学法人 筑波大学 癌の治療に使用するための組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4745099A (en) * 1985-02-06 1988-05-17 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for the treatment of the anemia of malignant tumors
JP2632014B2 (ja) * 1988-03-03 1997-07-16 中外製薬株式会社 骨髄機能障害性貧血治療剤
RU2111750C1 (ru) * 1995-02-23 1998-05-27 Институт элементоорганических соединений РАН Модификатор для противоопухолевой терапии
JPH1067678A (ja) * 1996-06-20 1998-03-10 Chugai Pharmaceut Co Ltd 肝疾患治療用医薬組成物
US20020052309A1 (en) * 1996-09-11 2002-05-02 Athanasius A. Anagnostou Method of treating endothelial injury

Also Published As

Publication number Publication date
CA2368618A1 (en) 2000-11-02
AU4486300A (en) 2000-11-10
RU2271829C2 (ru) 2006-03-20
KR100693796B1 (ko) 2007-03-12
NO20015227L (no) 2001-12-27
HUP0200840A3 (en) 2003-04-28
EP1212068A4 (en) 2007-03-14
WO2000064455A1 (en) 2000-11-02
KR20020000557A (ko) 2002-01-05
CN1352561A (zh) 2002-06-05
US6620779B2 (en) 2003-09-16
HUP0200840A2 (hu) 2002-07-29
CN1188137C (zh) 2005-02-09
NO20015227D0 (no) 2001-10-25
ZA200108012B (en) 2003-03-26
JP2002542296A (ja) 2002-12-10
BG64940B1 (bg) 2006-10-31
CA2368618C (en) 2011-03-01
NZ514521A (en) 2003-07-25
US6171620B1 (en) 2001-01-09
AU781301B2 (en) 2005-05-12
BR0010082A (pt) 2002-01-15
US20010000730A1 (en) 2001-05-03
US6426094B2 (en) 2002-07-30
IL146012A0 (en) 2002-07-25
US20020198153A1 (en) 2002-12-26
EP1212068A1 (en) 2002-06-12
PL350918A1 (en) 2003-02-10
BG106057A (en) 2002-04-30

Similar Documents

Publication Publication Date Title
US6426094B2 (en) Method of enhancing the efficacy of anti-tumor agents
Abdel-Razeq et al. Recent update in the pathogenesis and treatment of chemotherapy and cancer induced anemia
Kim et al. Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice
Zalupski et al. Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study
EP0224885A1 (en) Antitumor composition.
Schaake-Koning et al. Radiotherapy and cis-diammine dichloroplatinum (II) as a combined treatment modality for inoperable non-small cell lung cancer: a dose finding study
CN101522186B (zh) 有助于治疗癌症的方法、组合物和制品
Winczura et al. Combined treatment with cytoprotective agents and radiotherapy
Siena et al. Optimising management of neutropenia and anaemia in cancer chemotherapy—advances in cytokine therapy
AU2003203505B2 (en) Human transferrin for the treatment of anemia of chronic disease (ACD) and of functional iron deficiency
Valley Overview of cancer‐related anemia: focus on the potential role of darbepoetin alfa
Abdel-Razeq Cancer-related anemia
Ford et al. Strategies to optimize the use of erythropoietin and iron therapy in oncology patients.
Kolesar Novel approaches to anemia associated with cancer and chemotherapy
Inoue et al. Antitumor activity of quinocarmycin citrate (KW-2152) against human tumor xenografts serially transplanted into nude mice
RU2794024C1 (ru) Набор лекарственных препаратов для проведения курсовой третичной профилактики онкологических заболеваний для иммуномодулирующего воздействия при комбинированной терапии и способ третичной профилактики онкологических заболеваний с использованием комбинированной терапии с помощью набора лекарственных препаратов для иммуномодулирующего воздействия
Bellamy Fundamental concepts associated with combining cytotoxic drugs and x-irradiation
CN112168971B (zh) 抗vegf抗体和pdgf/pdgfr抑制剂在制备治疗表达fgf2肿瘤的药物的应用
Gonzalez et al. Continuous intravenous infusion combination chemotherapy for head and neck squamous cell carcinoma
Haas et al. Phase I trial of 5-fluorouracil by 24-hour infusion weekly
Ray Mitomycin C: a useful anticancer drug
WO2024216238A2 (en) Use of beta-catenin antagonist and immunomodulator
Weiss et al. A randomized phase I study of oral etoposide with or without granulocyte-macrophage colony-stimulating factor for the treatment of patients with advanced cancer
Amoroso et al. Cisplatin and 5-fluorouracil in refractory breast cancer patients: a phase II study
Glaspy Erythropoietins and Erythropoiesis 163 ed. by G. Molineux, MA Foote, and SG Elliott© 2003 Birkhäuser Verlag/Switzerland

Legal Events

Date Code Title Description
FG Grant or registration